Literature DB >> 16135771

Intravenous iron: how much is too much?

Tilman B Drüeke, Ziad A Massy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16135771     DOI： 10.1681/ASN.2005080804

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  5 in total

Review 1.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

2.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

3.  A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.

Authors:  Chia Chi Sun; Valentina Vaja; Shanzhuo Chen; Igor Theurl; Aaron Stepanek; Diane E Brown; Maria D Cappellini; Guenter Weiss; Charles C Hong; Herbert Y Lin; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-01-22       Impact factor: 5.992

Review 4.  Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

Authors:  Adam E Gaweda; Yelena Z Ginzburg; Yossi Chait; Michael J Germain; George R Aronoff; Eliezer Rachmilewitz
Journal:  Nephrol Dial Transplant       Date:  2014-05-12       Impact factor: 5.992

5.  Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease.

Authors:  Piotr Bartnicki; Paweł Fijałkowski; Małgorzata Majczyk; Jan Błaszczyk; Maciej Banach; Jacek Rysz
Journal:  Med Sci Monit       Date:  2013-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.